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Abstract In the human insulin gene, a regulatory sequence 
upstream of the transcription start site at 229 to 258 (the E2 
element) binds a ubiquitous factor USF. The present study led to 
the identification of a second factor, DO, that binds to an 
adjacent upstream site, the C2 element, that has previously not 
been described. The results demonstrate that DO exhibits similar 
properties to RIPE3bl, a factor shown to be an important 
determinant of insulin gene P-cell-specific expression. Binding of 
DO to the C2 element was abolished by the oxidising agent 
diamide, and the alkylating agent A'-ethylmaleimide. The results 
indicate that expression of the insulin gene may be regulated by a 
redox-dependent pathway involving RIPE3M or a RIPE3bl-like 
factor. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Transcription of the insulin gene is regulated for the most 
part by sequences located within a region spanning 350 base 
pairs from the transcription start site [1]. A number of ex-
acting elements have been characterised [2]. In the human 
insulin gene there are at least three A elements that bind a 
homeodomain factor, which plays an essential role in develop-
ment of the islets of Langerhans [3], and in the regulation of 
the insulin gene by glucose [4]. 
Other important regulatory sequences in the human insulin 
promoter include the C l element at —116 and two E box 
elements at —101 and —233. The equivalent C element in 
the rat insulin II gene has been extensively studied, and shown 
to bind a factor, R I P E 3 M [5-7], which has yet to be cloned 
and sequenced. R I P E 3 M may be important in the regulation 
of the insulin gene by glucose [8,9]. The proximal E element 
binds a basic helix-loop-helix factor, I E F 1 , that is a hetero-
dimer of NeuroD/Beta2 and the ubiquitous E2A gene product 
E47 [10,11]. The distal E element is more complex binding at 
least three factors, one of which has been identified as the 
ubiquitous factor U S F [12,13]. 
Since the distal E element lies within a transcriptionally 
important region of the human insulin promoter [14,15], the 
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current study was undertaken to characterise further the pro-
teins that bind at this site. The results show that there is 
another protein binding site adjacent to the E2 element. We 
show that this site, the C2 element, binds a RIPE3bl- l ike 
factor, the D N A binding activity of which is regulated in a 
redox-dependent manner. 
2. Materials and methods 
2.1. Chemicals and reagents 
Oligodeoxynucleotides were purchased from Alta Bioscience, Uni-
versity of Birmingham, Birmingham, UK and Cruachem Ltd, West of 
Scotland Science Park, Acre Rd, Glasgow, UK. Single-stranded com-
plementary oligonucleotides were annealed as previously described 
[16] and used as double-stranded probes labelled with [y-32P]ATP, 
or competitors, in electrophoretic mobility shift assays. An antibody 
specific for E47 was obtained from Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA. 
2.2. Preparation of nuclear extracts 
Nuclear extracts were prepared by a modification of a previously 
described method [17]. Cells were centrifuged for 30 s at 12000Xg 
and resuspended in 400 ill of ice-cold buffer containing 10 mM 
HEPES, pH 7.9, 10 mM KC1, 1 mM dithiothreitol and IX Protease 
Inhibitor Cocktail Solution (Boehringer Mannheim). Cells were al-
lowed to swell for 15 min on ice before adding 25 ul of 10% (v/v) 
Nonidet P-40. The cells were then vortexed for 15 s and centrifuged 
for 30 s at 12000Xg. The pellet was resuspended in 50 ul of ice-cold 
buffer containing 20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM dithio-
threitol, 1 X Protease Inhibitor Cocktail Solution and 5% (v/v) glycer-
ol. After vigorous shaking for 90 min, the nuclear extract was then 
centrifuged for 30 s at 12000Xg and 4°C in a microcentrifuge. The 
supernatant was collected, divided into small volumes and stored at 
-70°C. 
2.3. Electrophoretic mobility shift assays 
Electrophoretic mobility shift assays (EMSAs) were performed as 
previously described [16]. Nuclear extracts (2-4 ug of protein) were 
incubated with the 32P-labelled probe for 15 min at 4°C in buffer 
containing 25 mM Tris-HCl, pH 7.5, 50 mM KC1, 250 ng poly(dA-
dT).poly(dA-dT), 1 mM dithiothreitol, and 5% (v/v) glycerol. In redox 
experiments, dithiothreitol was omitted from the buffer. For competi-
tion experiments, the nuclear extract was incubated with 2.5-10.0 
pmol (approximately 50-200-fold excess) of unlabelled oligonucleotide 
for 15 min at 4°C before addition of the probe. In some experiments 
nuclear extracts were preincubated for 15 min at 4°C with 2 ul of anti-
E47 antibody or preimmune serum before addition of the probe. 
3. Results 
Two important criteria for optimal binding of individual 
transcription factors to D N A in vitro are the type of compet-
itor polynucleotide used to sequester non-specific D N A bind-
ing, and the length of D N A probe used. To investigate bind-
ing of proteins to the E2 region of the human insulin 
promoter, electrophoretic mobility shift assays were per-
formed using two oligonucleotide probes of different lengths, 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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DH1' 
<b) 
D H 1 ' AGCTGTGAGCACCGAC AGGTCTGGCCACCGGGCCCCTG 
D H l ' m l AGCTGTGAGlrCTfllC/JfCTAlrCTGGCCACCCiGOCCCClG 
DH1 'm2 AGCTGTGAGCAGGGACAGGTCTGGdTCTAlGGGCCCCTG 
DH 1 'm3 AGCTGTGAGfrCTAlGAfrCTAlrCTGGCflCTAlGGGCCCCTG 
D ACAGGTCTGGCCACCGGGCCCCTGGTTA 
E2 GTCTGGGCACCGGGCCCCTG 
C2 CTTAGCTGTGAGCAGGGACAGGTCTGGCGGA 
C2ml CTTAGCTGTGAdTCTAlG^TCTAIrCTGGCGGA 
C2m2 CITAGCTGTGACtlCTAIGACAGGTCTGGCGGA 
C2m3 CrlAGCTGTGAGGAGGGAtrCTAfTCTGGCGGA 
RIPE3b GATCTGGAAACTGCAGCTTCAGCCCCTCT 
RIPE3bml G A T G T G G A A A C T G C A _ G C T £ G ] A G C C C C T C T 
Fig. 1. CA(G/C)(G/C) sequences in the insulin gene promoter, a: 
Arrangement of regulatory sites in the rat I, rat II and human insu-
lin promoters with the position relative to the transcription start site 
indicated as negative numbers. The relative locations of the oligonu-
cleotides used in this study are represented by bold lines, b: Sequen-
ces of oligonucleotides used in this study. CA(G/C)(G/C) sequences 
are indicated by dashed lines. Boxed sequences represent base pair 
substitutions. Bracketed sequences represent linker sequences. Oligo-
nucleotides DR1, DR2, DR2m3 and B have been described previ-
ously [12]. 
D and DH1 ' (the sequences of oligonucleotides used in this 
study are given in Fig. 1), and a range of dissimilar polynu-
cleotides. Two major complexes, DO [12] and USF [13], and 
two minor complexes, XI and X2, were observed using oligo-
nucleotides D and DH1 ' as probes and an HIT T15 nuclear 
extract (Fig. 2). Formation of complexes DO and X2, were 
most efficient using the longer oligonucleotide DH1 ' as probe 
and poly(dA-dT) as non-specific competitor. Since oligonu-
cleotides D and DH' both contain the E2 element, these re-
sults suggested that sequences outside the E2 element might be 
involved in binding of the unidentified factor DO to DNA. 
Adjacent to the E2 element in the human insulin promoter 
is a region that contains a direct repeat of the sequence 
CAGG, and is henceforth referred to as the C2 region. To 
investigate whether factor DO recognises this site, two mutant 
oligonucleotides of DH1' were used. Oligonucleotide DHl 'ml 
contained critical mutations within the C2 site, i.e. CAGG to 
TCTA, while E2 completely lacked the C2 region. Using oli-
gonucleotide DH1' as probe, competition for the DO complex 
was observed with oligonucleotide DH1' but not with oligo-
nucleotides DHl 'ml , E2 nor an unrelated oligonucleotide 
Octl (Fig. 2c). Confirmation that the DO complex bound at 
a site distinct to the E2 element was obtained using several 
further mutant oligonucleotides of DH1 ' as probes and an 
HIT T15 nuclear extract. Oligonucleotide DHl'm2 contained 
critical mutations at the E2 site, i.e. CACC to TCTA, and 
DHl 'm3 at both the C2 and E2 sites. Oligonucleotide C2 
completely lacked the E2 site, while C2ml contained critical 
mutations within the C2 site, i.e. CAGG to TCTA. Formation 
of the DO complex was observed using DH1' , DHl 'm2 and 
C2 as probes, whereas mutations within DHl 'ml , DHl 'm3 
and C2ml abolished binding of the DO complex (Fig. 3a). In 
contrast, formation of the USF complex was observed with 
oligonucleotides DH1' , DHl 'ml and E2, but not with any 
other oligonucleotide (Fig. 3a). This result indicated that DO 
binds to the C2 region, and not to the E2 site. 
To determine whether both CAGG sequences are involved 
in binding of the DO complex to the C2 region, two further 
mutant oligonucleotides of C2 were used. Oligonucleotide 
C2m2 contained critical mutations at the upstream CAGG 
sequence, i.e. CAGG to TCTA, while C2m3 contained the 
same mutation but at the downstream CAGG site. Using 
Fig. 2. Binding of nuclear extract proteins to oligonucleotides D 
and DH1'. EMSA using oligonucleotides D (a) and DH1' (b) as 
probes and an HIT T15 nuclear extract. The nuclear extract was 
preincubated for 15 min at 4°C with 500 ng of the indicated poly-
nucleotide before addition of the probe, (c) EMSA using DH1' as 
probe and an HIT T15 nuclear extract. The indicated unlabelled 
competitor oligonucleotides were used at approximately 50-fold ex-
cess. The positions of the major complexes DO, USF, XI and X2 
are indicated. 
Fig. 3. Complex DO binds to the sequence CAGGGACAGG. a: 
EMSA using oligonucleotides DH1', DHl'ml, DHl'm2, DHl'm3, 
E2, C2 and C2ml as probes and an HIT T15 nuclear extract, b: 
EMSA using oligonucleotide C2 as probe and an HIT T15 nuclear 
extract. The unlabelled competitor oligonucleotides were used at ap-
proximately 50- and 200-fold excess as indicated. The positions of 
the major complexes DO, USF and X2 are indicated. 
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Fig. 4. The E47 antibody does not compete for binding of complex 
DO to oligonucleotide DHl'. EMSA using oligonucleotides DR1 
(a), DHl' (b) and DR2 (c) as probes, poly(dA-dT) as polynucleo-
tide and an HIT T15 nuclear extract. Nuclear extracts were preincu-
bated with 2 ul of anti-E47 antibody (E47) or preimmune serum 
(PI). The positions of the major complexes IEF1, DO, X2, EFD3 
and USF are indicated. 
oligonucleotide C2 as probe and an HIT T15 nuclear extract, 
competition for complex DO was not observed with oligonu-
cleotide C2ml at either 50- or 200-fold excess (Fig. 3b). In 
contrast, competition for the DO complex was observed with 
both C2m2 and C2m3 as competitors at 200-fold excess. This 
result suggests that both CAGG sequences might be involved 
in binding of DO to the C2 region. 
The DO complex shares similar binding characteristics with 
several other important insulin gene regulatory proteins; 
IEF1, RIPE3M and EFD3. IEF1 is a heterodimer of a class 
A protein E47 and a cell-specific HLH partner BETA2/ Neu-
roD [10,11], while RIPE3bl and EFD3 have yet to be fully 
characterised. To investigate whether factors DO and IEF1 are 
related, an oligonucleotide DR1, containing the E2 sequence 
from the rat insulin I gene was used. Two major complexes, 
IEF1 and USF were observed using oligonucleotide DR1 as 
probe, poly(dA-dT) as non-specific competitor and an HIT 
T15 nuclear extract. Confirmation of the identity of the 
IEF1 complex was obtained with an anti-E47 antibody that 
competed for binding of the IEF1 complex, but did not affect 
binding of USF (Fig. 4a). In contrast, the antibody failed to 
compete for formation of the DO complex using oligonucleo-
tide D H l ' as probe (Fig. 4b), or EFD3 using oligonucleotide 
DR2 as probe (Fig. 4c). These results indicated that the DO 
complex was not the insulin gene regulatory protein IEF1. 
To investigate whether factors DO and RIPE3M are related, 
an oligonucleotide RIPE3b, containing the RIPE3b (or Cl) 
sequence from the rat insulin II gene was used. A major com-
plex Rl was observed using oligonucleotide RIPE3b as probe 
and an HIT T15 nuclear extract. Confirmation that the Rl 
complex represented a RIPE3bl-like factor was obtained us-
ing a mutant form of this oligonucleotide, RIPE3bml, that 
has previously been shown to abolish binding of the RIPE3bl 
complex. Using RIPE3bml as probe and an HIT T15 nuclear 
extract only weak formation of the Rl complex was observed 
(Fig. 5a). Competition for complex Rl was observed with 
oligonucleotides RIPE3b, C2 and DR2, but not with C2ml 
and DR2m3 which contain critical mutations within their re-
spective binding sites for DO and EFD3. Lower complexes 
observed using RIPE3b as probe were competed for by the 
unrelated oligonucleotide B and most likely represent non-
specific binding factors. Further experiments directly com-
pared the effect of salt on binding of complexes to oligonu-
cleotides DHl ' , DR2 and RIPE3b. Formation of the major 
complexes DO, EFD3, USF and Rl were all abolished in 200 
mM and 400 mM salt using oligonucleotides DHl ' , DR2 and 
RIPE3b as probes, and an HIT T15 nuclear extract (Fig. 6a-
c). In contrast, formation of complex X2 to oligonucleotide 
D H l ' (Fig. 6a) and the P-cell-specific factor IUF1 to oligonu-
cleotide B (Fig. 6d) were still detected in 400 mM salt. To-
gether these results suggest that the factors responsible for the 
formation of complexes DO and EFD3 most likely represent 
RIPE3bl-like factors. 
In vitro binding of many mammalian transcription factors 
is regulated by the redox state of the protein (reviewed in 
[18]). To investigate the effect of redox conditions on the bind-
ing activity of the DO complex, the oxidising agent diamide 
was used. Using oligonucleotide C2 as probe, only weak for-
mation of the DO complex was observed when HIT T15 nu-
clear extract was treated with 10 mM diamide for 15 min at 
4°C before addition of the probe (Fig. 7a). To determine 
whether this effect is reversible, HIT T15 extract pre-incu-
bated with diamide was then treated with various concentra-
tions of the reducing agent 2-mercaptoethanol for 15 minutes 
at 4°C before addition of the probe. Partial DO binding ac-
tivity was restored using 0.1% 2-ME, whereas higher concen-
trations of 0.25% and 0.5% 2-ME, or 20 mM dithiothreitol 
(data not shown) resulted in the full restoration of DO binding 
activity. To determine whether this effect was specific, HIT 
T15 nuclear extract was treated with the alkylating agent N-
ethylmaleimide (NEM). Treatment of the extract with 10 mM 
NEM resulted in an almost complete loss of binding activity 
of the DO complex (Fig. 7b). In contrast to treatment with 
diamide, no restoration of binding activity for DO was ob-
served by further treatment with the reducing agents 2-ME 
or DTT. By comparison, binding of IUF1 to DNA was un-
affected by treatment of nuclear extract with 2-ME, DM or 
DTT (Fig. 7c). These results indicated that the DO complex 
binds to DNA in a redox-dependent manner. 
Fig. 5. The major binding complex DO is a RIPE3bl-like factor, a: 
EMSA using oligonucleotides RIPE3b and RIPE3bml as probes 
and an HIT T15 nuclear extract, b: EMSA using RIPE3b as probe 
and an HIT T15 nuclear extract. The indicated unlabelled competi-
tor oligonucleotides were used in approximately 50-fold excess. The 
position of the major complex Rl is indicated. 
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4. Discussion 
This study has demonstrated that the insulin gene complex 
DO binds to the sequence CAGGGACAGG, referred to as the 
C2 element, in the human insulin promoter. This sequence 
resembles the binding sites recognised by two other important 
insulin gene regulatory proteins, IEF1 (CATCTG) and RI-
PE3bl (CAGCTTCAGC). However, several lines of evidence 
suggest that the DO complex is not IEF1, but instead is related 
to the RIPE3M-binding complex. Firstly, an antibody specific 
for IEF1 is unable to compete for the DO complex. Secondly, 
oligonucleotide C2, is able to compete for binding of the 
RIPE3bl-like complex Rl , whereas oligonucleotide C2ml 
that contains critical mutations within the C2 element does 
not. And thirdly, whereas formation of IEF1 is relatively salt-
independent [12], binding of the complexes DO and Rl were 
abolished at ionic concentrations greater than 200 mM KC1. 
This study has also demonstrated that factor EFD3 repre-
sents a RIPE3bl-like factor. EFD3 was initially characterised 
as a P-cell enriched factor that binds to the sequence CAG-
GAG at position —217 in the rat insulin II gene [12]. The role 
of this factor in transcription of the rat insulin II gene has not 
yet been studied in detail, although a two-fold reduction in 
activity was observed by linker scanning mutagenesis of this 
region (—229 to —218) [5]. In contrast, DO binds at position 
—242 in the human insulin promoter, which lies adjacent to 
the E2 element. A previous study has shown that both the C2 
and E2 elements are located within a transcriptionally impor-
tant region of the promoter. Thus deletion of the region from 
—258 to —229 produced a 25-fold reduction in transcription 
activity [14]. The individual roles of the C2 and E2 sites within 
this region requires further investigation. 
RIPE3M is a P-cell-specific factor that was first identified as 
binding to the RIPE3 element located between positions —126 
to —86 in the rat insulin II gene [5-7]. The RIPE3 element 
behaves as a P-cell-specific enhancer element when linked to a 
heterologous minimal promoter [6,19] and is divided into two 
subelements, RIPE3a (-110 to -86) and RIPE3b (-126 to 
— 101). RIPE3M and a ubiquitous complex, RIPE3b2, com-
posed of at least three polypeptides (p58, p62 and pi 10) [20], 
recognise the RIPE3b element. Screening of a HIT cell cDNA 
library with a RIPE3b probe recently identified the Rip-1 
Fig. 6. Effect of salt concentration on the binding of nuclear extract 
proteins. EMSA using oligonucleotides DH1' (a), DR2 (b), RIPE3b 
(c) or B (d) as probe and an HIT T15 nuclear extract. The salt con-
centrations used in the binding buffer are indicated. The positions 
of the major complexes DO, USF, X2, EFD3, Rl and IUF1 are in-
dicated. 
Fig. 7. Complex DO binds to the insulin promoter in a redox-de-
pendent manner, a: EMSA using oligonucleotide C2 as probe and 
an HIT T15 nuclear extract. Nuclear extracts were preincubated 
with 10 mM diamide as indicated for 15 min at 4°C and then 
treated with 0.1%, 0.25% or 0.5% 2-mercaptoethanol (2-ME) respec-
tively for 15 min at 4°C before addition of the probe, b: EMSA us-
ing oligonucleotide C2 as probe and an HIT T15 nuclear extract. 
Nuclear extracts were preincubated with JV-ethylmaleimide (NEM) 
at the indicated concentration for 15 min at 4°C and then treated 
with 0.5% 2-ME or 20 mM dithiothreitol (DTT) before addition of 
the probe, c: EMSA using oligonucleotide B as probe and an HIT 
T15 nuclear extract. Nuclear extracts were treated with 0.5% 2-ME, 
10 mM diamide or 10 mM NEM as indicated for 15 min at 4°C be-
fore addition of the probe. The positions of the major complexes 
DO and IUF1 are indicated. 
protein which is most likely a component of the RIPE3b2-
binding complex [20]. The RIPE3W factor has not yet been 
isolated. 
In the rat I and rat II insulin gene promoters there is no 
equivalent sequence of the C2 element at a related position. 
However, a recent paper reported that in the rat I insulin gene 
at position —329 to —307 there is a related sequence (CACC) 
that binds the factor PAX6 [21]. In the pancreas, two Pax 
genes Pax4 and Pax6 are expressed, which possess a conserved 
sequence motif, the paired box, that encodes a DNA-binding 
domain [22]. Pax4 is required for normal development of pan-
creatic endocrine cells as mice homozygous for a null allele of 
Pax4 lack mature P- and 8-cells, while a-cells are present in 
higher numbers [23]. In contrast, the pancreas of Pax6 homo-
zygous mutant mice lack glucagon-producing cells, suggesting 
that Pax6 is essential for the differentiation of a-cells [24]. To 
date, there have been no reports that Pax4 or Pax6 can rec-
ognise sites within the human insulin promoter. However, 
based on the observation that RIPE3bl and PAX4/6 share 
similar binding sites and both have important roles in pancre-
atic islet hormone gene expression, a likely candidate gene for 
the factor RIPE3M is a member of the PAX family of verte-
brate genes. 
In recent years there have been major advances made in the 
identification and cloning of factors that bind to and activate 
the insulin gene. The new challenges now lie in understanding 
how the function of insulin gene factors are controlled within 
the P-cell. IUF1 (insulin upstream factor 1), for example, is a 
P-cell-specific factor that binds to at least three sites within the 
human insulin promoter [25]. Binding of IUF1 is triggered 
when islets of Langerhans are exposed to high glucose, and 
abolished by exposure to low glucose [4]. A recent study 
showed that glucose (a cellular stress) activates a specific kin-
ase, SAPK2 (stress-activated protein kinase), within the P-cell 
that in turn activates IUF1 indirectly by a novel IUFl-acti-
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vating enzyme [26]. Similarly, R I P E 3 M is a regulator of glu-
cose-mediated transcription of the insulin gene [8,9]. In par-
ticular R I P E 3 M binding activity has been shown to be stimu-
lated approximately eight-fold by glucose. This raises the 
question as to what mechanisms are involved in modulat ing 
D N A binding of R I P E b l . 
Oxidative stress can also modulate expression of certain 
genes, by pathways that most likely involve protein kinases 
[18]. However, an additional effect of oxidative stress is to 
directly modulate redox-sensitive regulatory factors through 
oxidation of sulphydryl residues. For example, the binding 
of many factors, including U S F [27], N F - K B [28], AP-1 [29] 
and PAX8 [30], is reduced or lost when critical cysteine resi-
dues are oxidised. In the present study we have demonstrated 
that binding of the RIPE3bl- l ike complex, DO, is reduced 
when the protein is treated with the oxidising agent, diamide. 
Binding of this factor can then be restored by treatment with 
a reducing agent such as 2-ME. Furthermore, this effect ap-
pears to be specific, as alkylation with N E M abolishes binding 
of the factor irreversibly. F r o m these results we can thus sug-
gest that one way in which insulin gene transcription might be 
controlled is by a redox-regulated pathway that affects bind-
ing of R I P E 3 M or a RIPE3bl- l ike factor. Experiments are 
currently under way to investigate whether changes in the 
redox environment of the P-cell can regulate expression of 
the insulin gene. 
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